

### **Reference list**

# CliniMACS<sup>®</sup> Flexible Labeling System

## Optimization of methodology for production of CD25/CD71 allodepleted donor T cells for clinical use

Albon S, Mancao C, Gilmour K, White G, Ricciardelli I, Brewin J, Lugthart G, Wallace R, Amrolia PJ Cytotherapy (2013) 15:109-121

#### Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale

Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, Aguilar B, Ostberg JR, Riddell SR, Forman SJ, Jensen MC J Immunother (2012) 35:689-701

#### Generation of CD19-chimeric antigen receptor modified CD8<sup>+</sup> T cells derived from virusspecific central memory T cells

Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR Blood (2012) 19: 72-82

#### Atransgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, Forman SJ, Riddell SR, Jensen MC Blood (2011) 118: 1255-1263

#### Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy

Samarasinghe S, Mancao C, Pule M, Nawroly N, Karlsson H, Brewin J, Openshaw P, Gaspar HB, Veys P, Amrolia PJ Blood (2010) 115: 396-407

#### Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma

Vari F, Munster DJ, Hsu JL, Rossetti TR, Mahler SM, Gray PP, Turtle CJ, Prue RL, Hart DNJ British Journal of Haematology (2008) 143: 374-377

### A large-scale method for the selective depletion of $\alpha\beta$ T lymphocytes from PBSC for allogeneic transplantation

Chaleff S, Otto M, Barfield RC, Leimig T, Iyengar R, Martin J, Holiday M, Houston J, Geiger T, Huppert V, Handgretinger R Cytotherapy (2007) 8: 746-754

#### CliniMACS<sup>®</sup> Cell Enrichment Using NKp46 — A Large Scale, Single-Step NK Cell Isolation Method.

Bondzio I, Schmitz J, Huppert V Blood (ASH Annual Meeting Abstracts 2007) 110: Abstract 3877

#### Immunotherapy of EBV Post Solid Organ Transplantation Lymphoproliferative Disease with Genetically Engineered Haploidentical T Cells.

Orchard PJ, Tolar J, Basso L, Brunstein C, Tomblyn M, Baker S, Blazar B, Wagner J, Miller JS Blood (ASH Annual Meeting Abstracts 2005) 106: Abstract 5541

#### Immunoselection of Functional CMRF-56+ Blood Dendritic Cells from Multiple Myeloma Patients for Immunotherapy.

Radford KJ, Turtle CJ, Kassianos AJ, Slavica Vuckovic, Gardiner D, Khalil D, Taylor K, Wright S, Gill D, Hart DNJ

1/2



Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact. The CliniMACS® System components: Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer are manufactured and controlled under an ISO 13485 certified quality system. In Europe, the CliniMACS System components are available as CE-marked medical devices. In the USA, the CliniMACS System components including the CliniMACS Reagents are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS<sup>®</sup> MicroBeads are for research use only and not for use in humans.

MACS and CliniMACS are registered trademarks or trademarks of Miltenyi Biotec GmbH. Copyright © 2010 Miltenyi Biotec GmbH. All rights reserve

2/2